Precigen, Inc. (NASDAQ:PGEN - Get Free Report) shares shot up 6.9% on Friday . The stock traded as high as $1.89 and last traded at $1.93. 497,440 shares changed hands during trading, a decline of 57% from the average session volume of 1,169,419 shares. The stock had previously closed at $1.80.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 target price on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Precigen in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.
View Our Latest Analysis on Precigen
Precigen Trading Down 6.0 %
The stock has a market capitalization of $502.81 million, a price-to-earnings ratio of -3.11 and a beta of 1.58. The stock's 50 day moving average is $1.64 and its 200 day moving average is $1.17.
Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.30 million. On average, sell-side analysts anticipate that Precigen, Inc. will post -0.32 EPS for the current year.
Hedge Funds Weigh In On Precigen
Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new stake in shares of Precigen in the fourth quarter valued at $27,000. Stifel Financial Corp raised its stake in Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 15,680 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 5,915 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Precigen during the 4th quarter worth about $35,000. Finally, RPO LLC acquired a new stake in shares of Precigen during the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 33.51% of the company's stock.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Further Reading
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
